DeCure for Fatal multiple mitochondrial dysfunctions syndrome
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for fatal multiple mitochondrial dysfunctions syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFatal multiple mitochondrial dysfunctions syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fatal multiple mitochondrial dysfunctions syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No drug treatment for multiple mitochondrial dysfunctions syndrome is described in these abstracts. The papers review the field of mitochondrial medicine generally. One abstract notes that more than 50 mtDNA mutations and several nuclear gene mutations had been identified by 1999, and that animal models were then expected to enable drug and gene therapy development. A 2013 abstract states that most patients with mitochondrial respiratory chain deficiency still lack a molecular diagnosis, because of the genetic heterogeneity of these disorders. A 2019 abstract discusses proteasome inhibition as a potential strategy for diseases linked to defective mitochondrial protein import, but provides no patient data, survival figures, or response rates.
Mitochondrial replacement therapy is reviewed in a 2018 paper as a possible way to eradicate a severely debilitating and often fatal disease, but the same abstract notes that despite supporting safety and efficacy data, social and legal barriers prevent its clinical use. No trial results, sample sizes, or survival outcomes are given. A 2020 review of mitochondrial genome variants in neurodegenerative diseases offers no treatment data for multiple mitochondrial dysfunctions syndrome.
What is missing is any clinical trial of a drug for this specific syndrome, any patient stratification strategy, and the funding needed to move from general mitochondrial biology to a tested therapy for a fatal paediatric disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
FEBS Letters · 1999 · 76 citations
Revolution in mitochondrial medicine
AbstractA revolution in chemical pathology occurred about 40 years ago with the discovery of a patient with mitochondrial dysfunction. The field of mitochondrial medicine has experienced explosive growth during the last decade. More than 50 mtDNA mutations and several nuclear gene mutations have been identified in affected patients. The recent development of animal models will continue the revolution in mitochondrial medicine by facilitating in depth studies of the molecular pathogenesis and development of novel drug and gene therapy strategies for mitochondrial dysfunction. As we enter the next millennium, we can expect mitochondrial medicine to remain a dynamic and rapidly developing field.
Scientific Reports · 2023 · 20 citations · open access
Recent advances and new perspectives in mitochondrial dysfunction
AbstractIn the last decade, there has been an increased appreciation for mitochondria as central hubs in diverse processes, such as cellular energy, immunity, and signal transduction. As such, we have become aware that mitochondrial dysfunction underlies many diseases, including primary (mutations in genes encoding mitochondrial proteins) and secondary mitochondrial diseases (mutations in non-mitochondrial genes critical for mitochondrial biology), as well as complex diseases with mitochondrial dysfunction (chronic or degenerative diseases). Evidence suggests that mitochondrial dysfunction may often precede other pathological signs in these disorders, further modulated by genetics, environment, and lifestyle.
Current Opinion in Obstetrics & Gynecology · 2018 · 8 citations
Mitochondrial replacement therapy
AbstractPURPOSE OF REVIEW: The present study briefly reviews the history of mitochondrial replacement therapy (MRT); however, the focus is on recent advancements and future directions of the field. Specifically addressing societal and legal concerns and advances in MRT. RECENT FINDINGS: There continue to be new ethical debates surrounding MRT. In addition, there have been advancements in MRT techniques which could improve potential outcomes. Furthermore, advances in genetics continue to provide alternative approaches to treatment of many diseases, including alternatives to MRT. SUMMARY: MRT may be beneficial to eradicate a severely debilitating and often fatal disease. Despite significant supporting safety and efficacy, there are still many social and legal barriers to instituting MRT to clinical practice.
EMBO Molecular Medicine · 2019 · 7 citations · open access
Stop wasting protein—Proteasome inhibition to target diseases linked to mitochondrial import
AbstractAbstract Mitochondrial dysfunction is linked to various human diseases. Symptoms can occur early in life or manifest progressively during life and include poor muscle coordination or weakness, neurological or developmental problems, or immunodeficiency (Lightowlers et al, 2015). Most mitochondrial diseases are caused by mutations in genes encoding mitochondrial proteins. Mutations can affect protein functions in many ways; they can not only impair enzymatic activities, but also lower protein stability, hamper assembly into multimeric protein complexes, or abrogate protein transport into mitochondria. Understanding the impact of mutations on protein function is crucial to understand pathophysiological mechanisms of mitochondrial diseases and to develop therapeutic approaches.
Molecular diagnosis in mitochondrial respiratory chain deficiency using exome sequencing
AbstractAims: Inherited mitochondrial diseases comprise a group of highly heterogeneous disorders that result in defective oxidative phosphorylation, which present with a wide spectrum of phenotypic features ranging from neonatal fatalities to late onset neurodegenerative disorders. Because of its genetic heterogeneity, identifying the cause for mitochondrial disorders remains a challenge and most patients lack a molecular diagnosis.
[Mitochondrial genome variants and neurodegenerative diseases].
AbstractNeurodegenerative diseases are a group of diseases characterized by chronic progressive damage to tissues of central nervous system and peripheral nervous system, which include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, etc. The etiology is mainly related to factors such as aging, genetics and environment. More and more evidence indicate that mitochondrial dysfunction plays a vital role in the pathogenesis of neurodegenerative diseases. Variants of mitochondrial genes, including point variants, deletions, and copy number variations, have been recognized as important factors modulating genetic susceptibility to such diseases. This paper has reviewed recent studies for the influence of mitochondrial variants on the pathogenesis of neurodegenerative diseases, in order to provide clues for the pathogenesis, diagnosis and development of new drugs for such disorders.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
